IPP Bureau
Samsung Biologics, Eli Lilly team up to launch major biotech hub in Korea
By IPP Bureau - March 17, 2026
The planned facility, to be built at Samsung’s Bio Campus II, is set to become a launchpad for up to 30 emerging biotech firms
BioDuro and Cenra API Solutions forge global API manufacturing joint venture in Taiwan
By IPP Bureau - March 17, 2026
The Taipei facility boasts 10 GMP API production lines, with a total reactor volume exceeding 350,000 liters
Cupid unveils “Made in India, Japanese Quality” branding to boost global presence
By IPP Bureau - March 17, 2026
The initiative comes through a collaboration with Asia’s oldest latex condom manufacturer
L&T Tech unveils AI-powered lung digital twin platform
By IPP Bureau - March 17, 2026
LTTS’ lung digital twin integrates seamlessly with CT imaging workflows, using deep learning to reconstruct a comprehensive 3D digital twin of the lungs
Johnson & Johnson reports promising early results for targeted bladder cancer therapy
By IPP Bureau - March 17, 2026
FGFR alterations are prevalent in early-stage bladder cancer, appearing in roughly 70% of intermediate-risk and 40% of high-risk NMIBC tumors
GSK expands RSV vaccine to younger adults in US, targeting high-risk 18–49 age group
By IPP Bureau - March 16, 2026
Previously, Arexvy was authorized for adults 60 and older, and for those 50–59 with heightened risk
Virta Health shows nutrition therapy may extend life in advanced pancreatic cancer
By IPP Bureau - March 16, 2026
The trial enrolled patients with stage IV pancreatic cancer, where median life expectancy is just 6 to 12 months
Aptar Pharma teams up with COVIRIX Medical to explore next-generation antiviral inhaler
By IPP Bureau - March 16, 2026
COVIRIX Medical says its broad-spectrum antiviral portfolio has already shown positive virology results against key pandemic threats
C2N Diagnostics expands Alzheimer’s blood test to South Korea via BeauBrain partnership
By IPP Bureau - March 16, 2026
Under the agreement, healthcare professionals in the country will gain access to C2N’s PrecivityAD2 blood test
First patient dosed in trial of novel drug targeting limb-threatening artery disease
By IPP Bureau - March 16, 2026
The trial will enroll up to 42 patients in Finland across four cohorts
Abbott study shows continuous glucose monitoring outperforms fingersticks in Type 2 diabetes
By IPP Bureau - March 16, 2026
This study demonstrates the power of real-time glucose information for people with Type 2 diabetes treated with basal insulin
Zuellig Pharma expands Cialis footprint across Asia
By IPP Bureau - March 16, 2026
The expanded ownership is expected to improve access to Cialis for millions of men in Asia affected by ED and BPH
QIAGEN bags FDA nod for full GI testing on QIAstat-Dx Rise system
By IPP Bureau - March 16, 2026
The approval means US laboratories can now run both respiratory and gastrointestinal panels on the high-throughput QIAstat-Dx Rise
